Abstract
Over the last few years, the use of interleukin-2 (IL-2) and lymphokine-activated killer (LAK) cells have been found to be effective in the treatment of some solid tumours and acute myeloid leukemia. Our patient was initially diagnosed as having bilateral synchronous renal cell cancer (RCC) and underwent nephrectomy. Approximately two years after the operation he developed leukopenia without any sign of residual renal cell cancer. Bone marrow examination revealed acute myeloblastic leukemia (AML). IL-2 following IFN-α2a was used as a maintenance therapy after a standard remission induction and a consolidation therapy. Our patient has been still disease free for 58 months after the diagnosis of AML and 71 months after the diagnosis renal cell cancer. Review of the literature showed that this is the first case who has both RCC and AML and was treated successfully with IL-2 and IFN-α2a.
Original language | English (US) |
---|---|
Pages (from-to) | 207-210 |
Number of pages | 4 |
Journal | Turkish Journal of Haematology |
Volume | 18 |
Issue number | 3 |
State | Published - 2001 |
Keywords
- ANLL
- IFN-α2a
- IL-2
- Renal cell cancer